BioGaia Pharma announces First Patient Enrolled in Phase I Clinical Study Evaluating BGP014 in mild to moderate ulcerative colitis (AUCH-1).
BioGaia Pharma received formal approval from relevant authorities to proceed with both of its planned clinical trials during summer 2021. Investigational Medical Products were delivered to sites Q4 2021 and screening began. The first patient was enrolled into AUCH-1 in February 2022.“We are pleased to have taken a significant step in the development of improved therapeutic options in ulcerative colitis treatment,” said Nigel Titford CEO of BioGaia Pharma. BGP014 is targeted to Ulcerative Colitis (UC). UC is a debilitating condition characterised by chronic inflammation in the intestinal